Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 27;14(1):e12309. doi: 10.1002/dad2.12309

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Changes in serum glycopeptide abundance in serum samples from Alzheimer's disease (AD) patients compared to controls using PLS‐DA. (A) The scores plot shows the distribution of participants across latent components 1 and 2 given the PLS‐DA model for glycopeptides. (B) Variables with VIP scores ≥1.5 and their VIP scores. Variable colored in red are those selected for differential analysis and are visualized in C‐E. (C‐E) Boxplots showing the differences in abundances of glycopeptides from control and AD samples. Protein complement factor I (CFAI), apolipoprotein B (apolipoprotein B) and Complement C3 (CO3). N‐glycan symbol key: yellow circles, galactose (Gal); green circles, mannose (Man); blue squares, N‐acetylglucosamine (GlcNAc); red triangles, fucose (Fuc); purple diamonds, N‐acetylneuraminic acid (Neu5Ac)